Tandem Diabetes Care (TNDM) Common Equity (2016 - 2025)
Historic Common Equity for Tandem Diabetes Care (TNDM) over the last 14 years, with Q3 2025 value amounting to $133.0 million.
- Tandem Diabetes Care's Common Equity fell 4406.42% to $133.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.0 million, marking a year-over-year decrease of 4406.42%. This contributed to the annual value of $263.1 million for FY2024, which is 1611.25% down from last year.
- Per Tandem Diabetes Care's latest filing, its Common Equity stood at $133.0 million for Q3 2025, which was down 4406.42% from $133.3 million recorded in Q2 2025.
- Tandem Diabetes Care's Common Equity's 5-year high stood at $449.6 million during Q2 2022, with a 5-year trough of $133.0 million in Q3 2025.
- Over the past 5 years, Tandem Diabetes Care's median Common Equity value was $314.0 million (recorded in 2023), while the average stood at $311.9 million.
- Per our database at Business Quant, Tandem Diabetes Care's Common Equity skyrocketed by 5127.91% in 2021 and then plummeted by 4406.42% in 2025.
- Quarter analysis of 5 years shows Tandem Diabetes Care's Common Equity stood at $433.1 million in 2021, then rose by 1.58% to $439.9 million in 2022, then dropped by 28.71% to $313.6 million in 2023, then decreased by 16.11% to $263.1 million in 2024, then crashed by 49.46% to $133.0 million in 2025.
- Its Common Equity stands at $133.0 million for Q3 2025, versus $133.3 million for Q2 2025 and $155.3 million for Q1 2025.